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Abstract
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More and more advanced radiotherapy techniques have been adopted for post-mastectomy
radiotherapies (PMRT). Patient dose reconstruction is challenging for these advanced techniques
because they increase the low out-of-field dose area while the accuracy of out-of-field dose
calculations by current commercial treatment planning systems (TPSs) is poor. We aim to measure
and model the out-of-field radiation doses from various advanced PMRT techniques. PMRT
treatment plans for an anthropomorphic phantom were generated, including volumetric modulated
arc therapy (VMAT) with standard and flattening-filter-free (FFF) photon beams, mixed beam
therapy, 4-field intensity modulated radiation therapy (IMRT), and Tomotherapy. We measured
doses in the phantom where the TPS calculated doses were lower than 5% of the prescription dose
using thermoluminescent dosimeters (TLD). The TLD measurements were corrected by two
additional energy correction factors, namely out-of-beam out-of-field (OBOF) correction factor
KOBOF and in-beam out-of-field (IBOF) correction factor KIBOF, which were determined by
separate measurements using an ion chamber and TLD. A simple analytical model was developed
to predict out-of-field dose as a function of distance from the field edge for each PMRT technique.
The root mean square discrepancies between measured and calculated out-of-field doses were
within 0.66 cGy/Gy for all techniques. The IBOF doses were highly scattered and should be
evaluated case by case. One can easily combine the measured out-of-field dose here with the infield dose calculated by the local TPS to reconstruct organ doses for a specific PMRT patient if the
same treatment apparatus and technique were used.
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1. Introduction
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Post-mastectomy radiotherapy (PMRT) is commonly used for patients with invasive breast
cancer after surgery to sterilize the residual tumor cells and has been shown to reduce local
recurrences and improve the overall survival (EBCTCG et al., 2014). More and more new
and advanced radiotherapy technologies have been adopted for PMRT: 4-field intensity
modulated radiation therapy (IMRT) was reported to have the best balance of target coverage
and normal tissue sparing compared with other PMRT techniques (Wang et al., 2015); bolus
electron conformal therapy (BECT) is an effective modality for PMRT, although it can cause
dose heterogeneity in some cases (Perkins et al., 2001; Kudchadker et al., 2002); the
methodology of BECT combined with IMRT for PMRT has been experimentally confirmed
with improved dose homogeneity (Kavanaugh et al., 2013); flattening-filter-free (FFF)
beams can potentially reduce the dose to organs at risk (Subramaniam et al., 2012); the
current standards of care for PMRT at our institution are volumetric modulated arc therapy
(VMAT) and Tomotherapy (Ashenafi et al., 2010; Nichols et al., 2014). Both modalities
provide good target coverage and dose homogeneity, but the large cloud of low dose
delivered to the normal tissues is of concern (Ashenafi et al., 2010; Nichols et al., 2014).

Author Manuscript

Radiotherapy can cause a spectrum of acute and chronic side effects for the breast cancer
patients (Neugut et al., 1993; Hojris et al., 1999; Gao et al., 2003; Darby et al., 2013;
Grantzau et al., 2013). According to the literature (Dorr and Herrmann, 2002; Diallo et al.,
2009), the majority of the second cancers were observed in the low or intermediate dose
areas. The advanced radiotherapy techniques like IMRT and Tomotherapy will increase the
low dose region because of the beam modulation (more monitor units) and the non-opposed
beam multiplicity (radiation is more spread out than in conformal radiotherapy). To quantify
a patient’s risk of developing radiogenic side effects after PMRT, accurate knowledge of the
patient dose (both primary and stray radiation doses) is essential. It is generally accepted that
commercial treatment planning systems (TPSs) severely underestimate dose at low dose
regions (Jang et al., 2008; Howell et al., 2010a; Huang et al., 2013; Joosten et al., 2013;
Wang and Ding, 2014; Jagetic and Newhauser, 2015).
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Out-of-field dose data based on measurements or Monte Carlo simulations for static and
IMRT photon fields were extensively reported in the literature (Stovall et al., 1995; Mutic
and Low, 1998; Mutic and Klein, 1999; Stern, 1999; Meeks et al., 2002; Kry et al., 2005;
Kry et al., 2006; Sharma et al., 2006; Wang and Xu, 2008; Bednarz and Xu, 2009; Ruben et
al., 2011; Halg et al., 2012; Kaderka et al., 2012; La Tessa et al., 2012; Taddei et al., 2013;
Covington et al., 2016), while analytical models of out-of-field dose from photon external
therapy had only been proposed in a few studies (McParland and Fair, 1992; Taddei et al.,
2013; Jagetic and Newhauser, 2015; Hauri et al., 2016). Most of the previous modeling
studies focused on open beams or conventional field-in-field beams, and the modeling of
IMRT beams required intensive information of each field (Hauri et al., 2016). None of the
previous studies proposed any analytical model to calculate out-of-field dose from PMRT
techniques.
Therefore, the objective of this study was to measure and model the out-of-field doses from
various advanced PMRT techniques. We measured the out-of-field doses by delivering
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various PMRT plans to an anthropomorphic phantom loaded with thermoluminescent
dosimeter (TLD). We corrected TLD measurements by additional energy correction factors,
and developed a simple analytical model to predict out-of-field doses based on the measured
data. Calculations of the risk of developing side effects after receiving each PMRT technique
or plan quality comparison is beyond the scope of this paper and will be reported in a
separate study.

2. Methods and Materials
2.1. Treatment planning

Author Manuscript

An Atom dosimetry adult male phantom with a breast attachment (CIRS, Inc., Norfork, VA)
was used for treatment planning and measurements (figure 1). The phantom is transected in
2.5 cm slices and each slice contains a 1.5 cm2 grid of holes to hold TLD rods. It was
scanned by a GE LightSpeed 16 Slice computed tomography (CT) scanner (GE Healthcare,
Little Chalfont, United Kingdom), and the CT images with 2.5 mm slice thickness were
imported into Pinnacle 9.8 TPS (Philips Healthcare, Amsterdam, Netherlands). Both
planning target volume (PTV) and organs at risk (OARs) were contoured on the phantom
and were approved by a board certified radiation oncologist (M Sanders) who is specialized
in breast cancer radiation oncology. The PTV included the left chest wall, left
supraclavicular area and axillary area, and internal mammary chain area. OARs included
bladder, brain, contralateral breast, colon, esophagus, heart, kidney, liver, lung, pharynx,
rectum, small intestine, spinal cord, stomach, thyroid and trachea.
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Various PMRT treatment plans were generated, including a standard VMAT, two FFF
VMAT with 6 MV (6x FFF VMAT) and 10 MV photons (10x FFF VMAT), BECT mixed
with IMRT and VMAT beams (mixed beam therapy), 4-field IMRT, and Tomotherapy. The
dose prescription was 50Gy administered in 25 fractions for all the plans. The following
criteria were met for each treatment plan to be considered clinically acceptable and therefore
representative of an actual plan administered to a patient: The volume of the PTV receiving
at least 95% of the prescribed dose is greater than or equal to 95% (NRGOncology, 2013);
the volume of lungs receiving at least 20 Gy is less than 20% (Marks et al., 2010); the
volume of heart receiving at least 22.5 Gy is less than 20% (Hardenbergh et al., 2001).
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All the VMAT plans were generated in Pinnacle 9.8 TPS and a dual-arc with 230° rotations
(between 180° and 310°) was used to cover the PTV. The beam geometry consisted of a 0
degree couch angle and a 45 degree collimator angle. The same beam setup was used for all
VMAT plans, while plan optimization was performed independently using the SmartArc
optimization algorithm in Pinnacle. The final plans required 12525 MUs (standard VMAT),
20900 MUs (6x FFF VMAT) and 25525 MUs (10x FFF VMAT).
Mixed beam therapy plan was generated in Pinnacle 9.8 TPS and .decimal p.d TPS (v5.1.9)
(.decimal LLC, Sanford, FL), and a single 16 MeV BECT electron beam was used to treat
the chest wall (20 fractions), two 10 MV anterior-posterior (AP) and posterior-anterior (PA)
IMRT beams were used to treat the supraclavicular area (20 fractions), and a 230° dual-arc 6
MV VMAT (5 fractions) was optimized on top of the dose distribution from the first 20
fractions to treat the whole PTV and improve the dose homogeneity. The p.d TPS was used
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to create the electron bolus that provided the best coverage of the distal surface of the BECT
PTV by the 90% isodose surface. More details about the mixed beam planning will be
reported in a separate study from our group. The final mixed beam plan required 18925
MUs.
4-field IMRT plan was generated in Pinnacle 9.8 and three 6 MV IMRT beams with gantry
angles of 295°, 315° and 150° and one 10 MV IMRT beam with gantry angle of 170° were
used to cover the whole PTV. The final 4-field IMRT plan required 17200 MUs.
For Tomotherapy, the CT images and contours in Pinnacle were imported into
TomoTherapy® Hi·Art TPS (Accuray, Madison, WI) for plan optimization. Parameters for
Tomotherapy plan optimization included a pitch of 0.287, a modulation factor of 2.8, 5.02
cm field width, and the final plan required 87525 MUs.

Author Manuscript

The collapsed cone convolution (CCC) photon dose calculation algorithm (Ahnesjo and
Aspradakis, 1999) in Pinnacle with a dose grid of 4×4×4 mm3 and in TomoTherapy® Hi·Art
TPSs with a fine dose grid was used to calculate photon beam doses, and the pencil beam
redefinition algorithm (Shiu and Hogstrom, 1991) in the .decimal p.d planning software and
the pencil beam algorithm (Hogstrom et al., 1981) in the Pinnacle TPS with a dose grid of
4×4×4 mm3 were used to calculate electron beam doses. A 1 cm Superflab bolus was placed
on the ipsilateral chest wall for all treatment techniques for the purpose of dose buildup
except the BECT component of the mixed beam therapy. All the plans were comparable to
the standard PMRT patient plans in our clinic and were reviewed and approved by the
radiation oncologist.
2.2. Out-of-field dose measurements

Author Manuscript

2.2.1. TLD dosimetry—TLD dosimeter was used in this study and each TLD rod
contained approximately 45 mg TLD-100 (LiF:Mg,Ti) powder. The TLD rods were read
using a REXON UL-320 Reader (Rexon Components, Inc., Beachwood, OH). The TLD
powder in each rod was divided into three samples of approximately 15 mg each and the
three samples were used to determine the mean dose for each TLD rod. All TLDs were
stored for two days before reading to minimize the fading effect.

Author Manuscript

The literature showed that commercial TPSs cannot calculate dose accurately at low out-offield dose regions (<5% of prescription dose) (Howell et al., 2010a; Wang and Ding, 2014),
and the TLD measurement points in this study were therefore chosen at places where TPS
calculated doses were lower than 5% isodose. The measurement points in OARs were
selected uniformly in each organ, and the same measurement points were used for all the
PMRT techniques throughout this study. TLD was not placed at a certain point if the TPS
calculated dose at that point was in-field (greater than 5 % isodose) for a given PMRT
technique. Since contralateral breast attachment has no TLD holes, 5 TLD packets
(approximately 1×1×0.2 cm3) were placed on the surface of the breast attachment and
another 5 packets were placed between the breast attachment and the phantom. Table 1
shows the number of TLDs used in different organs for each plan, and it does not list
stomach because stomach was almost completely in field for all the PMRT techniques.
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After measurement points were determined and TLD rods were loaded in the phantom, the
phantom was irradiated for each PMRT technique. All VMAT plans, mixed beam therapy
(IMRT with additional VMAT) and 4-field IMRT were delivered by Elekta Versa HD™ with
a 160-leaf Agility multi-leaf collimator (MLC) (Elekta, Crawley, United Kingdom) which
was calibrated according to the American Association of Physicists in Medicine (AAPM)
Task Group 51 calibration protocol (Almond et al., 1999). Electron component of the mixed
beam therapy was not delivered because out-of-field dose contribution from electron beam is
considered to be negligible. Tomotherapy was delivered by TomoTherapy® (Accuray,
Madison, WI) which was calibrated according to the AAPM Task Group 148 calibration
protocol (Langen et al., 2010). For plans with multiple beam energies such as 4-field IMRT
and mixed beam therapy, we performed separate TLD calibrations and measurements for
each photon energy since TLD response is energy dependent: we delivered beams with one
energy to the anthropomorphic phantom loaded with TLD rods first, did TLD calibration for
that energy, unloaded the phantom and plugged in new TLD rods and delivered beams with
another energy, did TLD calibration for the new energy. As for TLD calibrations, we
sandwiched a TLD packet in solid water phantoms, delivered a known dose to the TLD
packet using the radiation beam of a specified energy, and recorded the TLD reading. This
was repeated for several dose levels and a calibration curve was created based on the
readings. The total TLD dose was calculated by summing doses from all energies. To ensure
sufficient linearity in TLD response, we delivered four fractions with 2 Gy per fraction,
which would deliver approximately 40 cGy at 5 % isodose line. The uncertainty of the dose
measured by each TLD is ≤ 4% according to the literature (Kirby et al., 1992; Ito et al.,
2011).
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2.2.2. TLD out-of-field energy corrections—It is known that TLD response in the outof-field region needs additional energy corrections due to the change of incident spectrum of
photons (Scarboro et al., 2011; Mijnheer et al., 2013). The TLD dose was calculated as
following:
(1)
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where D is the absorbed dose, T is the raw TLD reading, S is the system sensitivity factor,
KL is the linearity correction factor, KOBOF is out-of-beam out-of-field energy correction
factor, which means this correction factor applies to the area that is not only out of the high
dose region but also out of the path of any radiation beam. The reason we define this TLD
correction factor as KOBOF instead of the previously used KNR (non-reference energy
correction factor) (Scarboro et al., 2011) is that we want to distinguish it from the in-beam
out-of-field correction factor (KIBOF) defined later in this section. Scarboro et al. (2011)
measured KNR factors, which are the same as KOBOF in this study, for 6 MV open photon
beams and their correction factor ranged from 0.88 to 0.99. For IMRT beams and higher
photon energies, however, this information is lacking.
For rotational radiotherapies like VMAT or Tomotherapy, a point can be in the low dose
region but is located within the path of the theoretically rotational open beam coming from
the widest jaw opening in the plan. There is a little dose contribution from the primary beam
Phys Med Biol. Author manuscript; available in PMC 2018 November 13.
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incident toward the point because there is a minimum gap limit between the opposing
MLCs, although the point is blocked by the MLCs most of the time due to beam modulation.
This point can be regarded as in-beam out-of-field (IBOF), as shown in figure 2. For this
region, TLD correction factor should be different from OBOF region because energy
spectrum here contains more high energy components and Eq. (1) should be replaced by

(2)

For open field and fixed-beam IMRT, KIBOF should not be used because out-of-field region
(< 5% of prescription dose) is always outside the path of beams coming from the maximum
collimator openings.

Author Manuscript
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In this study, ion chamber (IC) measurement was used as the reference dosimeter since the
nominal photon energy range for the PTW Farmer-type IC (N30013 PTW Farmer®
Ionization Chamber, PTW, Freiburg, Germany) has the lower end as 30 keV, while it was
reported that mean photon energy at out-of-field location was greater than 170 keV for 6
MV photon beams (Scarboro et al., 2011), which is significantly higher than the lower limit
of the IC. Therefore IC’s over-response in the out-of-field region is negligible, which is also
consistent with the literature (Kry et al., 2017). To quantify KOBOF and KIBOF for all PMRT
techniques, we transferred PMRT treatment plans from the anthropomorphic phantom to a
water phantom in Pinnacle TPS and performed out-of-field dose measurements with TLDs
and an IC in solid water phantoms. For VMAT and mixed beam therapy plans, OBOF doses
were measured at 23, 28 and 33 cm away from the beam axis and at 5 and 10 cm depths (in
AP direction) (figure 2). IBOF doses were measured at 6 and 10 cm from beam axis and at
10 and 15 cm depths (in AP direction) in the phantom and we made sure the doses at those
IBOF points were lower than 5% of prescription dose by checking the dose distribution in
TPS (figure 2). For IMRT plans (4-field IMRT), OBOF doses were measured at 21.5, 25 and
30 cm away from the beam axis and at 5 and 10 cm depths (in AP direction) and there was
no IBOF point for 4-field IMRT beams. The measurement results were used to obtain
KOBOF and KIBOF for a given PMRT technique, and they can be calculated as the ratio of
measured doses from IC and TLD.
TLD measurement points were separated into two groups: OBOF and IBOF. For each group,
KOBOF and KIBOF correction factors were applied accordingly.
2.3. Out-of-field dose modeling
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A simple analytical model was used to fit the out-of-field dose data and the model was
chosen based on the best balance between accuracy and complexity. The expected dose at
the out-of-field points (DOF) can be calculated by

(3)
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where DRX is the prescription dose, d is the distance from the field edge (50% isodose line)
in mm unit, C1, C2, C3 and t are the fitting parameters determined by each treatment
technique.
In Pinnacle, we first created a contour based on 50% isodose surface for the
anthropomorphic phantom, and identified TLD hole positions on each slice. We then
exported the 50% contour as a DICOM format and imported it into MATLAB. The distance
from the 50% contour to each TLD measurement point was calculated by seeking the
minimum distance from all points in the 50% surface to the TLD location. The fitting
parameters were adjusted by minimizing the total root mean square deviation (RMSD)
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(4)

for each TLD location, i, evaluated for n TLD locations.
2.4. Mean organ dose reconstruction and comparison with TPS calculations
To further illustrate the necessity of the investigation of the out-of-field doses from various
PMRT techniques, the mean organ doses were reconstructed based on a volume-weighting
method (Howell et al., 2010b) and were compared with the organ doses predicted by the
TPS alone: each organ volume (Vorgan) was divided by 5% isodose line based on the TPS
calculated dose, such as greater than 5% (
dose. For the region

Author Manuscript

organ were averaged (

) and lower than 5% (

) of prescription

, corrected TLD doses from equation (1, 2) in the corresponding
). Otherwise, TPS predicted average dose

in the volume

was used for the region
. The mean organ dose (Dorgan) was reconstructed by a
volume-weighting equation

(5)

Author Manuscript

Although 8 Gy was delivered to the phantom to ensure TLD linearity, the final organ doses
were scaled to the prescription dose of 50 Gy since this is the standard prescription for
PMRT patients. The mean organ doses calculated by the TPS alone were also extracted for
comparison.

3. Results
It was found that the additional TLD correction factors (KOBOF and KIBOF) have little
dependence on off-axis distance or depth for the same technique. For simplicity, the average
values were used as the correction factors for each PMRT technique (table 2). The KIBOF
factor was always 1.0, which revealed the photon energy is high in the IBOF region and the
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additional TLD energy correction is not necessary in these areas for the PMRT techniques
evaluated in this study. The same KOBOF for 6x FFF VMAT was used for Tomotherapy
considering the similarity between these two rotational techniques.
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Figure 3 shows measured out-of-field doses versus distance from the field edge for different
PMRT techniques and the doses were scaled up to match the prescription dose of 50 Gy. For
VMAT plans (figure 3(a–c)), doses at IBOF points (open circles) showed a different pattern
from OBOF points (solid circles) since they were exposed to the primary beams during
gantry rotation. For mixed beam therapy, there were no pure IBOF points because IBOF
points for VMAT beam were OBOF points for supraclavicular IMRT beams. The doses at
IBOF+OBOF points (figure 3(d), open triangle) were much closer to doses at OBOF points.
For 4-field IMRT (figure 3(e)), all the measurement points were OBOF points. For
Tomotherapy (figure 3(f)), there were no IBOF measurements since all potential IBOF
locations were within the 5% prescription isodose line. Also, the measured doses were
scattered and higher than the others near the field edge. Except for Tomotherapy, the number
of MU used in each PMRT technique was not correlated with the out-of-field doses or organ
doses.

Author Manuscript

The analytical model was used to fit the measured out-of-field data and the dose curves
predicted by the model were plotted in figure 3 along with the measured data. The model
parameter values and the RMSD (in cGy/Gy) between measured and calculated doses for
each treatment technique were listed in table 3. Only OBOF doses were used in the fittings
except “mixed beam therapy-2nd fit” in which IBOF+OBOF points were also included
because they were close to OBOF doses. The dashed line in figure 3(d) represented this
second fit and the RMSD increased compared to the first fit as shown in table 3. As shown in
figure 3(a–c), the doses at IBOF points from VMAT plans were highly scattered and did not
follow any obvious trend, and a model fit for these locations was therefore not attempted.
Based on equation (5), mean organ doses were reconstructed and shown in table 4. Stomach
was not shown here because TLD measurements were not performed. Mean organ doses
calculated by Pinnacle TPS were also listed in the table and the agreement between TPS
calculations and those based on the new method was poor. TPS underestimated organ doses
in most cases and the discrepancy was up to 2.3 cGy/Gy.

4. Discussion

Author Manuscript

In this study, we measured out-of-field doses from various advanced PMRT techniques, and
also developed a simple analytical model to predict out-of-field doses for each technique.
Our results show that OBOF doses from different PMRT techniques approximately follow a
simple polynomial model, while IBOF doses from rotational therapy like VMAT were
highly scattered because the IBOF region was exposed to the rotational narrow open beam
and the dose is mainly determined by the exposure time and dose rate. The TPS
underestimated the out-of-field doses and organ doses in most cases.
As we mentioned previously, the out-of-field data from advanced PMRT were largely
lacking in the literature and comparing our data or model with previous studies is difficult
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because the out-of-field dose depends on treatment machine and techniques. Despite that,
some of our qualitative findings agreed with previous studies: TPS systematically
underestimates out-of-field doses; the KOBOF values for 6MV photon beams are consistent
with the previous study (Scarboro et al., 2011); Tomotherapy has higher out-of-field doses at
most locations compared to other techniques (Mutic and Low, 1998; Meeks et al., 2002; Xu
et al., 2008). This can be explained by the fact that radiation was not limited enough due to
the characteristic of Tomotherapy (the beam is continuously delivered from 360 degrees
around the phantom and more MU is used) and possibly less peripheral shielding in
Tomotherapy units; dosimetric results between standard and FFF beams were comparable
for breast radiotherapies (Subramaniam et al., 2012; Spruijt et al., 2013; Wang et al., 2014),
although Subramaniam et al. (2012) claimed some improved sparing of contralateral organs
with FFF beams which was not observed in this study. This was possibly because the out-offield doses were not considered in their work, and different treatment machines and plan
optimization methods were used in the two studies.
Our study has several particular strengths. First, to the best knowledge of the authors’, we
measured and compared the out-of-field doses for various advanced PMRT technique for the
first time. Second, we corrected the TLD measurements with additional energy correction
factors. We introduced a new TLD correction factor, KIBOF, which will improve the
accuracy of out-of-field dose measurement and calculation for rotational radiotherapies like
VMAT and Tomotherapy. Third, a simple analytical model was developed to predict the outof-field doses from those advanced PMRT techniques with a reasonable accuracy. This
model can be used in the clinic directly while the more sophisticated model (Hauri et al.,
2016) may need more time to be implemented for clinical usage.
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One limitation of our study is that out-of-field doses in figure 3 and organ doses in table 4
were based on measurements within a generic phantom, while the actual dose delivered to a
real patient may be different from this study. As we mentioned in the introduction section,
our goal is to measure and model the out-of-field doses, and table 4 was only used to
demonstrate the necessity of using an improved way to determine out-of-field doses and
calculate organ doses. Most real PMRT patients only have CT images from mouth to upper
abdomen and it is impossible to reconstruct all the organ doses like what was done for this
phantom. Also considering the relatively low magnitude of out-of-field dose and the small
variation of photon energy spectra with field size and depth (Xu et al., 2008; Scarboro et al.,
2011), the absolute difference between the measured out-of-field doses here and the actual
out-of-field dose delivered to the patients is small. One can easily combine the measured
out-of-field dose here by looking up the out-of-field dose versus distance curves with the infield dose calculated by the local TPS to reconstruct organ doses for any PMRT patient if
they use the same treatment apparatuses and techniques used in this study. Second, we did
not measure the out-of-field dose from the electron component of the mixed beam therapy,
while the bremsstrahlung photon tail for 16 MeV electron beam is on the order of 3~4% of
the maximum dose. This x-ray contamination could slightly increase ipsilateral lung dose
and stomach dose since they are in the direction of the electron beam. The effect on other
organ doses should be negligible. Finally, we only measured the additional TLD correction
factors (KOBOF and KIBOF) for the PMRT techniques used in this study, while these
corrections factor may vary for other treatment techniques and beam energies.
Phys Med Biol. Author manuscript; available in PMC 2018 November 13.
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Comprehensive evaluation of these correction factors in various conditions will be the next
logical step of our research.

5. Conclusion
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In summary, we have measured out-of-field doses for various advanced PMRT techniques
using TLDs, proposed and measured additional TLD correction factors using TLDs and an
IC, and found the TPS underestimated the out-of-field doses and organ doses in most cases.
A simple analytical model was developed and could be used to predict the out-of-field doses
for each PMRT technique. Based on our findings, it is necessary to determine out-of-field
doses and use a hybrid approach to correctly reconstruct normal tissue doses for PMRT
patients. We focused on PMRT only and did not investigate other types of breast cancer
radiotherapies because of time and resource limitations. Investigation of out-of-field doses
from breast conserving radiotherapies will broaden the generality of the methodology
developed in this study, and this work is currently underway in our laboratory.

References

Author Manuscript
Author Manuscript

Ahnesjo A, Aspradakis MM. Dose calculations for external photon beams in radiotherapy. Phys Med
Biol. 1999; 44:R99–155. [PubMed: 10588277]
Almond PR, Biggs PJ, Coursey BM, Hanson WF, Huq MS, Nath R, Rogers DW. AAPM’s TG-51
protocol for clinical reference dosimetry of high-energy photon and electron beams. Med Phys.
1999; 26:1847–70. [PubMed: 10505874]
Ashenafi M, Boyd RA, Lee TK, Lo KK, Gibbons JP, Rosen, Fontenot JD, Hogstrom KR. Feasibility of
postmastectomy treatment with helical TomoTherapy. Int J Radiat Oncol Biol Phys. 2010; 77:836–
42. [PubMed: 19879697]
Bednarz B, Xu XG. Monte Carlo modeling of a 6 and 18 MV Varian Clinac medical accelerator for infield and out-of-field dose calculations: development and validation. Phys Med Biol. 2009; 54:N43–
57. [PubMed: 19141879]
Covington EL, Ritter TA, Moran JM, Owrangi AM, Prisciandaro JI. Technical Report: Evaluation of
peripheral dose for flattening filter free photon beams. Med Phys. 2016; 43:4789. [PubMed:
27487896]
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, Correa C, Cutter D,
Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic
heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013; 368:987–98.
[PubMed: 23484825]
Diallo I, Haddy N, Adjadj E, Samand A, Quiniou E, Chavaudra J, Alziar I, Perret N, Guerin S,
Lefkopoulos D, de Vathaire F. Frequency distribution of second solid cancer locations in relation to
the irradiated volume among 115 patients treated for childhood cancer. Int J Radiat Oncol Biol
Phys. 2009; 74:876–83. [PubMed: 19386434]
Dorr W, Herrmann T. Cancer induction by radiotherapy: dose dependence and spatial relationship to
irradiated volume. J Radiol Prot. 2002; 22:A117–21. [PubMed: 12400959]
EBCTCG, McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R,
Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy after mastectomy and axillary surgery
on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data
for 8135 women in 22 randomised trials. Lancet. 2014; 383:2127–35. [PubMed: 24656685]
Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women
treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;
56:1038–45. [PubMed: 12829139]
Grantzau T, Mellemkjaer L, Overgaard J. Second primary cancers after adjuvant radiotherapy in early
breast cancer patients: a national population based study under the Danish Breast Cancer
Cooperative Group (DBCG). Radiother Oncol. 2013; 106:42–9. [PubMed: 23395067]
Phys Med Biol. Author manuscript; available in PMC 2018 November 13.

Yoon et al.

Page 11

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Halg RA, Besserer J, Schneider U. Systematic measurements of whole-body dose distributions for
various treatment machines and delivery techniques in radiation therapy. Med Phys. 2012;
39:7662–76. [PubMed: 23231314]
Hardenbergh PH, Munley MT, Bentel GC, Kedem R, Borges-Neto S, Hollis D, Prosnitz LR, Marks
LB. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and
doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys. 2001; 49:1023–8. [PubMed:
11240243]
Hauri P, Halg RA, Besserer J, Schneider U. A general model for stray dose calculation of static and
intensity-modulated photon radiation. Med Phys. 2016; 43:1955. [PubMed: 27036591]
Hogstrom KR, Mills MD, Almond PR. Electron beam dose calculations. Phys Med Biol. 1981;
26:445–59. [PubMed: 6787621]
Hojris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart
disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with
or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy
Committee of the Danish Breast Cancer Cooperative Group. Lancet. 1999; 354:1425–30.
[PubMed: 10543669]
Howell RM, Scarboro SB, Kry SF, Yaldo DZ. Accuracy of out-of-field dose calculations by a
commercial treatment planning system. Phys Med Biol. 2010a; 55:6999–7008. [PubMed:
21076191]
Howell RM, Scarboro SB, Taddei PJ, Krishnan S, Kry SF, Newhauser WD. Methodology for
determining doses to in-field, out-of-field and partially in-field organs for late effects studies in
photon radiotherapy. Phys Med Biol. 2010b; 55:7009–23. [PubMed: 21076193]
Huang JY, Followill DS, Wang XA, Kry SF. Accuracy and sources of error of out-of field dose
calculations by a commercial treatment planning system for intensity-modulated radiation therapy
treatments. J Appl Clin Med Phys. 2013; 14:4139. [PubMed: 23470942]
Ito S, Parker BC, Levine R, Sanders ME, Fontenot J, Gibbons J, Hogstrom K. Verification of
calculated skin doses in postmastectomy helical tomotherapy. Int J Radiat Oncol Biol Phys. 2011;
81:584–91. [PubMed: 21300469]
Jagetic LJ, Newhauser WD. A simple and fast physics-based analytical method to calculate therapeutic
and stray doses from external beam, megavoltage x-ray therapy. Phys Med Biol. 2015; 60:4753–
75. [PubMed: 26040833]
Jang SY, Liu HH, Mohan R. Underestimation of low-dose radiation in treatment planning of intensitymodulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 71:1537–46. [PubMed: 18513883]
Joosten A, Matzinger O, Jeanneret-Sozzi W, Bochud F, Moeckli R. Evaluation of organ-specific
peripheral doses after 2-dimensional, 3-dimensional and hybrid intensity modulated radiation
therapy for breast cancer based on Monte Carlo and convolution/superposition algorithms:
implications for secondary cancer risk assessment. Radiother Oncol. 2013; 106:33–41. [PubMed:
23351844]
Kaderka R, Schardt D, Durante M, Berger T, Ramm U, Licher J, La Tessa C. Out-of-field dose
measurements in a water phantom using different radiotherapy modalities. Phys Med Biol. 2012;
57:5059–74. [PubMed: 22836598]
Kavanaugh JA, Hogstrom KR, Chu C, Carver RA, Fontenot JP, Henkelmann G. Delivery confirmation
of bolus electron conformal therapy combined with intensity modulated x-ray therapy. Med Phys.
2013; 40:021724. [PubMed: 23387747]
Kirby TH, Hanson WF, Johnston DA. Uncertainty analysis of absorbed dose calculations from
thermoluminescence dosimeters. Med Phys. 1992; 19:1427–33. [PubMed: 1461205]
Kry SF, Bednarz B, Howell RM, Dauer L, Followill D, Klein E, Paganetti H, Wang B, Wuu CS,
George Xu X. AAPM TG 158: Measurement and calculation of doses outside the treated volume
from external-beam radiation therapy. Med Phys. 2017 [Epub ahead of print].
Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, Rosen. Out-of-field photon and
neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy. Int J Radiat
Oncol Biol Phys. 2005; 62:1204–16. [PubMed: 15990026]

Phys Med Biol. Author manuscript; available in PMC 2018 November 13.

Yoon et al.

Page 12

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Kry SF, Titt U, Ponisch F, Followill D, Vassiliev ON, White RA, Mohan R, Salehpour M. A Monte
Carlo model for calculating out-of-field dose from a varian 6 MV beam. Med Phys. 2006;
33:4405–13. [PubMed: 17153419]
Kudchadker RJ, Hogstrom KR, Garden AS, McNeese MD, Boyd RA, Antolak JA. Electron conformal
radiotherapy using bolus and intensity modulation. Int J Radiat Oncol Biol Phys. 2002; 53:1023–
37. [PubMed: 12095572]
La Tessa C, Berger T, Kaderka R, Schardt D, Korner C, Ramm U, Licher J, Matsufuji N, Vallhagen
Dahlgren C, Lomax T, Reitz G, Durante M. Out-of-field dose studies with an anthropomorphic
phantom: comparison of X-rays and particle therapy treatments. Radiother Oncol. 2012; 105:133–
8. [PubMed: 22575675]
Langen KM, Papanikolaou N, Balog J, Crilly R, Followill D, Goddu SM, Grant W 3rd, Olivera G,
Ramsey CR, Shi C. QA for helical tomotherapy: report of the AAPM Task Group 148. Med Phys.
2010; 37:4817–53. [PubMed: 20964201]
Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, El Naqa I, Hubbs JL,
Lebesque JV, Timmerman RD, Martel MK, Jackson A. Radiation dose-volume effects in the lung.
Int J Radiat Oncol Biol Phys. 2010; 76:S70–6. [PubMed: 20171521]
McParland BJ, Fair HI. A method of calculating peripheral dose distributions of photon beams below
10 MV. Med Phys. 1992; 19:283–93. [PubMed: 1584119]
Meeks SL, Paulino AC, Pennington EC, Simon JH, Skwarchuk MW, Buatti JM. In vivo determination
of extra-target doses received from serial tomotherapy. Radiother Oncol. 2002; 63:217–22.
[PubMed: 12063012]
Mijnheer B, Beddar S, Izewska J, Reft C. In vivo dosimetry in external beam radiotherapy. Med Phys.
2013; 40:070903. [PubMed: 23822404]
Mutic S, Klein EE. A reduction in the AAPM TG-36 reported peripheral dose distributions with
tertiary multileaf collimation. American Association of Physicists in Medicine Task Group 36. Int
J Radiat Oncol Biol Phys. 1999; 44:947–53. [PubMed: 10386654]
Mutic S, Low DA. Whole-body dose from tomotherapy delivery. Int J Radiat Oncol Biol Phys. 1998;
42:229–32. [PubMed: 9747842]
Neugut AI, Robinson E, Lee WC, Murray T, Karwoski K, Kutcher GJ. Lung cancer after radiation
therapy for breast cancer. Cancer. 1993; 71:3054–7. [PubMed: 8490833]
Nichols GP, Fontenot JD, Gibbons JP, Sanders ME. Evaluation of volumetric modulated arc therapy
for postmastectomy treatment. Radiat Oncol. 2014; 9:66. [PubMed: 24571913]
NRGOncology. Standard or Comprehensive Radiation Therapy in Treating Patients with Early-Stage
Breast Cancer Previously Treated with Chemotherapy and Surgery. 2013
Perkins GH, McNeese MD, Antolak JA, Buchholz TA, Strom EA, Hogstrom KR. A custom threedimensional electron bolus technique for optimization of postmastectomy irradiation. Int J Radiat
Oncol Biol Phys. 2001; 51:1142–51. [PubMed: 11704339]
Ruben JD, Lancaster CM, Jones P, Smith RL. A comparison of out-of-field dose and its constituent
components for intensity-modulated radiation therapy versus conformal radiation therapy:
implications for carcinogenesis. Int J Radiat Oncol Biol Phys. 2011; 81:1458–64. [PubMed:
20950947]
Scarboro SB, Followill DS, Howell RM, Kry SF. Variations in photon energy spectra of a 6 MV beam
and their impact on TLD response. Med Phys. 2011; 38:2619–28. [PubMed: 21776799]
Sharma SD, Upreti RR, Deshpande DD. Use of peripheral dose data from uniform dynamic multileaf
collimation fields to estimate out-of-field organ dose in patients treated employing sliding window
intensity-modulated radiotherapy. Phys Med Biol. 2006; 51:2987–95. [PubMed: 16723779]
Shiu AS, Hogstrom KR. Pencil-beam redefinition algorithm for electron dose distributions. Med Phys.
1991; 18:7–18. [PubMed: 2008174]
Spruijt KH, Dahele M, Cuijpers JP, Jeulink M, Rietveld D, Slotman BJ, Verbakel WF. Flattening filter
free vs flattened beams for breast irradiation. Int J Radiat Oncol Biol Phys. 2013; 85:506–13.
[PubMed: 22672750]
Stern RL. Peripheral dose from a linear accelerator equipped with multileaf collimation. Med Phys.
1999; 26:559–63. [PubMed: 10227359]

Phys Med Biol. Author manuscript; available in PMC 2018 November 13.

Yoon et al.

Page 13

Author Manuscript
Author Manuscript

Stovall M, Blackwell CR, Cundiff J, Novack DH, Palta JR, Wagner LK, Webster EW, Shalek RJ. Fetal
dose from radiotherapy with photon beams: report of AAPM Radiation Therapy Committee Task
Group No. 36. Med Phys. 1995; 22:63–82. [PubMed: 7715571]
Subramaniam S, Thirumalaiswamy S, Srinivas C, Gandhi GA, Kathirvel M, Kumar KK, Mallik S,
Babaiah M, Pawar Y, Clivio A, Fogliata A, Mancosu P, Nicolini G, Vanetti E, Cozzi L. Chest wall
radiotherapy with volumetric modulated arcs and the potential role of flattening filter free photon
beams. Strahlenther Onkol. 2012; 188:484–90. [PubMed: 22402870]
Taddei PJ, Jalbout W, Howell RM, Khater N, Geara F, Homann K, Newhauser WD. Analytical model
for out-of-field dose in photon craniospinal irradiation. Phys Med Biol. 2013; 58:7463–79.
[PubMed: 24099782]
Wang B, Xu XG. Measurements of non-target organ doses using MOSFET dosemeters for selected
IMRT and 3D CRT radiation treatment procedures. Radiat Prot Dosimetry. 2008; 128:336–42.
[PubMed: 17627959]
Wang J, Li X, Deng Q, Xia B, Wu S, Liu J, Ma S. Postoperative radiotherapy following mastectomy
for patients with left-sided breast cancer: A comparative dosimetric study. Medical dosimetry:
official journal of the American Association of Medical Dosimetrists. 2015; 40:190–4. [PubMed:
25534167]
Wang L, Ding GX. The accuracy of the out-of-field dose calculations using a model based algorithm in
a commercial treatment planning system. Phys Med Biol. 2014; 59:N113–28. [PubMed:
24925858]
Wang Y, Vassil A, Tendulkar R, Bayouth J, Xia P. Feasibility of using nonflat photon beams for wholebreast irradiation with breath hold. J Appl Clin Med Phys. 2014; 15:4397. [PubMed: 24423835]
Xu XG, Bednarz B, Paganetti H. A review of dosimetry studies on external-beam radiation treatment
with respect to second cancer induction. Phys Med Biol. 2008; 53:R193–241. [PubMed:
18540047]

Author Manuscript
Author Manuscript
Phys Med Biol. Author manuscript; available in PMC 2018 November 13.

Yoon et al.

Page 14

Author Manuscript
Author Manuscript
Author Manuscript

Figure 1.

An Atom dosimetry phantom with a contralateral breast attachment on the right and a bolus
used in this study to cover the irradiated area on the left.
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Figure 2.

Author Manuscript

A schematic diagram of out-of-beam out-of-field (OBOF) and in-beam out-of-field (IBOF)
energy correction factors measurement setup. TLD and IC were located at the yellow marks
and the red mark represents the isocenter. A VMAT plan delivery is shown here with gantry
rotating in a cross-plane direction. The IMRT plan is not shown here and only OBOF
measurements were performed for IMRT beams.
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Figure 3.

Measured out-of-field doses versus distance from the field edge for various PMRT treatment
techniques overlaid by the analytical model fit to the measured data. Only OBOF doses were
used in the fittings except the second fit of mixed beam therapy doses in which IBOF
+OBOF points were also included. The dashed line in figure 3(d) represented this second fit.
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Mean out-of-beam out-of-field correction factor (KOBOF) and in-beam out-of-field correction factor (KIBOF)
for different PMRT techniques. Dashed table entry indicates the correction does not apply to that technique.
The standard deviation (σ) is reported as one standard deviation of the mean.
TLD correction factors
PMRT Technique
KOBOF (σ)

KIBOF (σ)

VMAT

0.93 (0.02)

1.0 (0.01)

6x FFF VMAT

0.87 (0.02)

1.0 (0.01)

10x FFF VMAT

0.84 (0.01)

1.0 (0.01)

Mixed beam therapy

0.88 (0.01)

1.0 (0.01)

4-field IMRT

0.83 (0.01)

-
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1130
1000
1100
1290
1810
1510
1170

6x FFF VMAT

10x FFF VMAT

Mixed Beam Therapy-1st fit

Mixed Beam Therapy-2nd fit

4-field IMRT

Tomotherapy

C1

VMAT

PMRT Technique

3.25

2.9

3.4

3.5

2.67

2.72

3.45

C2

0.003

0.0036

0.0034

0.0037

0.0015

0.0031

0.0058

C3

Coefficients

90

156

160

143

130

115

113

t (mm)

0.66

0.59

0.63

0.39

0.20

0.22

0.33

RMSD (cGy/Gy)

PMRT techniques. Only OBOF doses were used in the fittings except “mixed beam therapy-2nd fit” in which IBOF+OBOF points were also included in
the fitting.

Fitting parameters for the analytical model and root mean square deviation (RMSD) between the model calculated and the measured data for different
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41.3
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New

6xFFF VMAT

555.2

542.7

254.7

22.7

195

0

50.8

1136.1

579.5

354

970.5

647

31.5

159.9

0

0

TPS

567.6

541.5

266.6

34.7

212.1

7.8

74.4

1156.6

587.3

348.4

970.5

641.4

38.1

177.2

20.3

7.3

New

10xFFF VMAT

376.4

482

228.2

36.5

165.4

0

54.5

1409.7

339.1

389.3

1176.7

327.1

51.7

156.7

0

0

TPS

406.4

455.8

214.5
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New

Mixed beam therapy

Mean organ dose (cGy)

191.1

287.4

60.3

6.7

41.6
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0

904.9

281.1

162
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222.8

21
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16.6

77.3

902.5

270.9

133.9

573.8

230.0

41.7

277.8

26.2

17.1

New

4-field IMRT

1021.8

1239.4

290.6

62.4

1611.7

8.6

118.2

1234.1

1640.6

1647.8

708.5

1051.5

78.6

425.5

19.3

8.8

TPS

1021.8

1239.4

296.1

84.5

1611.7

12.2

126.5

1234.1

1640.6

1647.8

708.5

1051.5

94.4

431.4
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Values of mean organ doses for the CIRS phantom for various PMRT techniques, calculated based on the new volume-weighting method (New) and by
the TPS alone (TPS). Prescription dose was 50 Gy for all techniques. (CL Breast: contralateral breast)

Author Manuscript

Table 4
Yoon et al.
Page 20

Phys Med Biol. Author manuscript; available in PMC 2018 November 13.

